Cargando…

Targeting Tumor-Associated Macrophages to Increase the Efficacy of Immune Checkpoint Inhibitors: A Glimpse into Novel Therapeutic Approaches for Metastatic Melanoma

SIMPLE SUMMARY: Stimulation of the host immune responses, through the use of biotech drugs that remove a brake on the immune system (immune checkpoint inhibitors), is a current widely used strategy to treat a variety of advanced-stage tumors with impressive outcomes also in patients refractory to st...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ceci, Claudia, Atzori, Maria Grazia, Lacal, Pedro Miguel, Graziani, Grazia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7698460/ https://www.ncbi.nlm.nih.gov/pubmed/33212945 http://dx.doi.org/10.3390/cancers12113401

Ejemplares similares

Role of VEGFs/VEGFR-1 Signaling and Its Inhibition in Modulating Tumor Invasion: Experimental Evidence in Different Metastatic Cancer Models
por: Ceci, Claudia, et al.
Publicado: (2020)

Role of VEGFR‐1 in melanoma acquired resistance to the BRAF inhibitor vemurafenib
por: Atzori, Maria Grazia, et al.
Publicado: (2019)

The Anti-Vascular Endothelial Growth Factor Receptor 1 (VEGFR-1) D16F7 Monoclonal Antibody Inhibits Melanoma Adhesion to Soluble VEGFR-1 and Tissue Invasion in Response to Placenta Growth Factor
por: Atzori, Maria Grazia, et al.
Publicado: (2022)

Neuropilin-1 as Therapeutic Target for Malignant Melanoma
por: Graziani, Grazia, et al.
Publicado: (2015)

Platelet-derived growth factor-C promotes human melanoma aggressiveness through activation of neuropilin-1
por: Ruffini, Federica, et al.
Publicado: (2017)

Neuropilin-1 expressing melanoma cells as a model to study the aggressiveness of metastatic melanoma
por: Ruffini, Federica, et al.
Publicado: (2015)

At the Cutting Edge against Cancer: A Perspective on Immunoproteasome and Immune Checkpoints Modulation as a Potential Therapeutic Intervention
por: Tundo, Grazia R., et al.
Publicado: (2021)

Ellagic Acid Inhibits Bladder Cancer Invasiveness and In Vivo Tumor Growth
por: Ceci, Claudia, et al.
Publicado: (2016)

Experimental Evidence of the Antitumor, Antimetastatic and Antiangiogenic Activity of Ellagic Acid
por: Ceci, Claudia, et al.
Publicado: (2018)

Efficacy of immune checkpoint inhibitors in different types of melanoma
por: Rossi, Ernesto, et al.
Publicado: (2020)

Approaching coronavirus disease 2019: Mechanisms of action of repurposed drugs with potential activity against SARS-CoV-2
por: Lisi, Lucia, et al.
Publicado: (2020)

PDIA3 Expression in Glioblastoma Modulates Macrophage/Microglia Pro-Tumor Activation
por: Chiavari, Marta, et al.
Publicado: (2020)

The anti-vascular endothelial growth factor receptor-1 monoclonal antibody D16F7 inhibits invasiveness of human glioblastoma and glioblastoma stem cells
por: Atzori, Maria Grazia, et al.
Publicado: (2017)

Role of PARP Inhibitors in Cancer Immunotherapy: Potential Friends to Immune Activating Molecules and Foes to Immune Checkpoints
por: Franzese, Ornella, et al.
Publicado: (2022)

A novel and atypical NF-KB pro-inflammatory program regulated by a CamKII-proteasome axis is involved in the early activation of Muller glia by high glucose
por: Sbardella, Diego, et al.
Publicado: (2022)

Melanoma cells with acquired resistance to dabrafenib display changes in miRNA expression pattern and respond to this drug with an increase of invasiveness, which is abrogated by inhibition of NF-κB or the PI3K/mTOR signalling pathway
por: Caporali, Simona, et al.
Publicado: (2015)

Antitumor activity of a novel anti-vascular endothelial growth factor receptor-1 monoclonal antibody that does not interfere with ligand binding
por: Graziani, Grazia, et al.
Publicado: (2016)

Efficacy of immune checkpoint inhibitors for in-transit melanoma
por: Nan Tie, Emilia, et al.
Publicado: (2020)

New therapeutic approaches to metastatic gastroenteropancreatic neuroendocrine tumors: A glimpse into the future
por: Cidon, Esther Una
Publicado: (2017)

Checkpoint Inhibitors Immunotherapy in Metastatic Melanoma: When to Stop Treatment?
por: De Risi, Ivana, et al.
Publicado: (2022)

Cardiovascular Immunotoxicity Associated with Immune Checkpoint Inhibitors in Metastatic Melanoma
por: L’Orphelin, Jean-Matthieu, et al.
Publicado: (2023)

Correction: Efficacy of immune checkpoint inhibitors for in-transit melanoma
Publicado: (2020)

Combining checkpoint inhibitors and BRAF-targeted agents against metastatic melanoma
por: Cooper, Zachary A., et al.
Publicado: (2013)

Combining targeted therapy and immune checkpoint inhibitors in the treatment of metastatic melanoma
por: Kim, Teresa, et al.
Publicado: (2014)

Combined checkpoint inhibitor therapy causing diabetic ketoacidosis in metastatic melanoma
por: Changizzadeh, Pouyan N., et al.
Publicado: (2017)

Hyperprogression in Pediatric Melanoma Metastatic to the Breast Treated with a Checkpoint Inhibitor
por: Bernal Vaca, Laura, et al.
Publicado: (2019)

Survival after checkpoint inhibitors for metastatic acral, mucosal and uveal melanoma
por: Klemen, Nicholas D., et al.
Publicado: (2020)

Real-World Impact of Immune Checkpoint Inhibitors in Metastatic Uveal Melanoma
por: Bol, Kalijn Fredrike, et al.
Publicado: (2019)

Immune checkpoint inhibitor‐related gastritis in a patient with metastatic melanoma
por: Sugiyama, Yuya, et al.
Publicado: (2021)

A glimpse of the connection between PPARγ and macrophage
por: Yu, Lexiang, et al.
Publicado: (2023)

Clinical efficacy of T-cell therapy after short-term BRAF-inhibitor priming in patients with checkpoint inhibitor-resistant metastatic melanoma
por: Borch, Troels Holz, et al.
Publicado: (2021)

Early analysis of surrogate endpoints for metastatic melanoma in immune checkpoint inhibitor trials
por: Petrelli, Fausto, et al.
Publicado: (2016)

Targeted and Checkpoint Inhibitor Therapy of Metastatic Malignant Melanoma in Germany, 2000–2016
por: Hellmund, Peter, et al.
Publicado: (2020)

Future role for adoptive T-cell therapy in checkpoint inhibitor-resistant metastatic melanoma
por: Borch, Troels Holz, et al.
Publicado: (2020)

Immune checkpoint inhibitors in advanced or metastatic mucosal melanoma: a systematic review
por: Li, Jiarui, et al.
Publicado: (2020)

Real-world analyses of therapy discontinuation of checkpoint inhibitors in metastatic melanoma patients
por: Machado, Marina Amaral de Ávila, et al.
Publicado: (2020)

Toxicity, Response and Survival in Older Patients with Metastatic Melanoma Treated with Checkpoint Inhibitors †
por: de Glas, Nienke A., et al.
Publicado: (2021)

Mutated processes predict immune checkpoint inhibitor therapy benefit in metastatic melanoma
por: Patterson, Andrew, et al.
Publicado: (2022)

Biomarkers for Outcome in Metastatic Melanoma in First Line Treatment with Immune Checkpoint Inhibitors
por: Mesti, Tanja, et al.
Publicado: (2023)

Machine Learning Improves the Prediction of Responses to Immune Checkpoint Inhibitors in Metastatic Melanoma
por: Tabari, Azadeh, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_702ueqt31uu7s597rs4volrcv1